Fluidigm Corporation (NASDAQ:FLDM)’s share price reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $2.71 and last traded at $2.71, with a volume of 291,492 shares changing hands. The stock had previously closed at $3.15.

Several equities analysts have recently issued reports on FLDM shares. Zacks Investment Research raised Fluidigm Corporation from a “sell” rating to a “hold” rating in a report on Thursday, June 1st. ValuEngine lowered Fluidigm Corporation from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd.

The stock’s market capitalization is $107.07 million. The firm’s 50-day moving average is $3.70 and its 200 day moving average is $4.85.

Fluidigm Corporation (NASDAQ:FLDM) last announced its quarterly earnings data on Thursday, August 3rd. The medical research company reported ($0.58) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.02. Fluidigm Corporation had a negative net margin of 74.05% and a negative return on equity of 121.04%. The company had revenue of $23.90 million during the quarter, compared to analyst estimates of $23.50 million. During the same period in the previous year, the business earned ($0.63) EPS. The firm’s revenue for the quarter was down 15.2% on a year-over-year basis. On average, equities research analysts predict that Fluidigm Corporation will post ($2.19) EPS for the current year.

In other Fluidigm Corporation news, Director Evan/ Fa Jones sold 10,900 shares of the business’s stock in a transaction on Wednesday, June 7th. The shares were sold at an average price of $4.54, for a total transaction of $49,486.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Steven Mcphail bought 20,000 shares of the firm’s stock in a transaction on Tuesday, August 8th. The shares were bought at an average price of $3.00 per share, with a total value of $60,000.00. Following the completion of the purchase, the insider now owns 27,842 shares in the company, valued at approximately $83,526. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 4,106,038 shares of company stock valued at $13,496,083. Company insiders own 4.70% of the company’s stock.

A number of large investors have recently made changes to their positions in FLDM. Metropolitan Life Insurance Co. NY increased its stake in shares of Fluidigm Corporation by 3.1% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 20,789 shares of the medical research company’s stock worth $151,000 after buying an additional 632 shares during the last quarter. AQR Capital Management LLC acquired a new stake in shares of Fluidigm Corporation during the fourth quarter worth about $119,000. Norges Bank acquired a new stake in shares of Fluidigm Corporation during the fourth quarter worth about $1,196,000. Acadian Asset Management LLC increased its stake in shares of Fluidigm Corporation by 46.0% in the first quarter. Acadian Asset Management LLC now owns 301,705 shares of the medical research company’s stock worth $1,716,000 after buying an additional 95,056 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its stake in shares of Fluidigm Corporation by 0.9% in the first quarter. Russell Investments Group Ltd. now owns 2,258,937 shares of the medical research company’s stock worth $12,849,000 after buying an additional 19,725 shares during the last quarter. Institutional investors and hedge funds own 91.41% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/19/fluidigm-corporation-fldm-sets-new-1-year-low-at-2-71-updated.html.

Fluidigm Corporation Company Profile

Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.

Receive News & Stock Ratings for Fluidigm Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm Corporation and related stocks with our FREE daily email newsletter.